GlaxoSmithKline (GSK) today became the fifth drug manufacturer to loosen or end its 340B contract pharmacy restrictions in Arkansas and [...] …
Month: October 2023
The recent end of a 340B program waiver for hospitals is wrong, hurts hospitals and their patients, and is bound [...] …
Federal courts should allow enforcement of Arkansas’ 340B contract pharmacy law to continue unimpeded, an attorney representing Arkansas told a [...] …
SPONSORED CONTENT
The 340B program, enacted in 1992, enables covered entities to stretch scarce federal resources as far as possible, reaching more eligible patients and providing more comprehensive services.
In 2010, the 340B program was expanded under the Affordable Care Act, allowing covered entities to contract with an unlimited number
…
The community benefits provided by 340B hospitals surged by $16.5 billion, or 24%, in the latest year analyzed by a [...] …
The Health Resources and Services Administration (HRSA) confirmed today it is ending a 340B program waiver issued early in the [...] …
Genentech, Sanford Health, and Carolina Health Centers’ 340B reform group, 340B Working Table, spent $110,000 on lobbying and gained eight [...] …
SPONSORED CONTENT
With so many challenges facing health systems today — from 340B contract pharmacy restrictions to drug shortages, labor issues, and ever-rising costs — revenue integrity has become essential to financial stability.
With huge increases in drug expenditures from pre-pandemic levels, health systems must
…
Rep. Mike Johnson (R-La.), the new speaker of the U.S. House, has received campaign donations from multiple 340B stakeholders but [...] …
GlaxoSmithKline (GSK) recently restricted 340B pricing on Jesduvroq, an anemia treatment, when providers dispense it through contract pharmacies. GSK contractor [...] …